Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
pharmaceutical_companies:emergent_biosolutions [2022/08/22 00:16]
pamela
pharmaceutical_companies:emergent_biosolutions [2022/10/06 02:25] (current)
pamela [COVID-19]
Line 25: Line 25:
  
 Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal
 +
 by Angus Liu | Jul 18, 2017 by Angus Liu | Jul 18, 2017
  
Line 34: Line 35:
  
  
-===== COVID-19 =====+===== COVID-19 Vaccines =====
  
 In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o)) In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o))
 +
 +
 +==== Manufacturing Disaster ====
 +{{ :pharmaceutical_companies:emergent_vaccine_site_shut_down.png?400|}}
 +FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys
 +April 19, 2021 by Kevin Dunleavy 
 +
 +Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long.
 +
 +Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to stop producing drug substance there. 
 +
 +In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times reported  an additional batch of between 10 million and 15 million doses of the AZ vaccine was lost last November because of suspected contamination at the plant.  ((https://web.archive.org/web/20210419145104/https://www.fiercepharma.com/pharma/at-request-fda-emergent-s-troubled-baltimore-plant-suspends-j-j-vaccine-production))
Back to top